We show that tofacitinib reduces the levels of the pro-angiogenic factors CD147 and TIMP-1 both in an in vitro co-culture system of fibroblast and monocytic cell lines (Figure 1) and in the serum samples obtained from RA patients treated with tofacitinib (Figure 7). The gene discussed is TIMP1; the disease is rheumatoid arthritis.